The benefit of SHINGRIX on PHN can be attributed to the effect of the vaccine on the prevention of HZ. A further reduction of PHN incidence in subjects with confirmed HZ could not be demonstrated due to the limited number of HZ cases in the vaccine group. 1
* Pooled data from study ZOE-50 and ZOE-70. Modified Total Vaccinated Cohort (mTVC) was the primary efficacy analysis and included all subjects randomized in the study who received a second dose of the vaccine and did not develop a confirmed case of shingles within one month after the second dose. Subjects were followed prospectively development of PHN. PHN was defined as shingles-associated pain rated as 3 or greater on a 0-10 scale occurring or persisting at least 90 days following the onset of rash using the Zoster Brief Pain Inventory questionnaire.
† SHINGRIX is not indicated for prevention of primary varicella infection or for the treatment of herpes zoster (HZ) or postherpetic neuralgia (PHN).